The -842G/C Polymorphisms of PIN1 Contributes to Cancer Risk: a Meta-analysis of 10 Case-control Studies

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2013 Sep 10

PMID 24013949

Citations 1

Authors

Hui-Rong Xu

Zhong-Fa Xu

Yan-Lai Sun

Jian-Jun Han

Zeng-Jun Li

Affiliations

Soon will be listed here.

Abstract

Background: Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (PIN1) plays an important role in cancer development. The relationship between PIN1 -842G/C (rs2233678) polymorphism and cancer risk was inconclusive according to published literature.

Methodology/principal Findings: A literature search, up to February 2013, was carried out using PubMed, EMBASE and the China National Knowledge Infrastructure (CNKI) database. A total of 10 case-control studies including 4619 cases and 4661 controls contributed to the quantitative analysis. Odds ratio (OR) and 95% confidence intervals (95% CI) were used to assess the strength of association. Overall, individuals with the variant CG (OR = 0.728, 95% CI: 0.585,0.906; Pheterogeneity<0.01) and CG/CC (OR = 0.731, 95% CI: 0.602,0.888; Pheterogeneity<0.01) genotypes were associated with a significantly reduced cancer risk compared with those with wild GG genotype. Sub-group analysis revealed that the variant CG (OR = 0.635, 95% CI: 0.548,0.735; Pheterogeneity = 0.240) and CG/CC (OR = 0.645, 95% CI: 0.559,0.744, Pheterogeneity = 0.258) genotypes still showed an reduced risk of cancer in Asians; while no significant association was observed in Caucasians (CG vs.GG: OR = 0.926, 95% CI: 0.572,1.499, Pheterogeneity<0.01; CG/CC vs. GG: OR = 0.892, 95% CI: 0.589,1.353; Pheterogeneity<0.01). Furthermore, sensitivity analysis confirmed the stability of results. Begg's funnel plot and Egger's test did not reveal any publication bias.

Conclusions: This meta-analysis suggests that the PIN1 -842G/C polymorphism is associated with a significantly reduced risk of cancer, especially in Asian populations.

Citing Articles

Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.

Luo M, Gong C, Chen C, Lee D, Hu H, Huang P Cancer Res. 2014; 74(13):3603-16.

PMID: 24786790 PMC: 4079726. DOI: 10.1158/0008-5472.CAN-13-2785.

References

Wulf G, Ryo A, Wulf G, Lee S, Niu T, Petkova V . Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J. 2001; 20(13):3459-72. PMC: 125530. DOI: 10.1093/emboj/20.13.3459. View

Segat L, Milanese M, Crovella S . Pin1 promoter polymorphisms in hepatocellular carcinoma patients. Gastroenterology. 2007; 132(7):2618-9. DOI: 10.1053/j.gastro.2007.04.037. View

Lu J, Yang L, Zhao H, Liu B, Li Y, Wu H . The polymorphism and haplotypes of PIN1 gene are associated with the risk of lung cancer in Southern and Eastern Chinese populations. Hum Mutat. 2011; 32(11):1299-308. DOI: 10.1002/humu.21574. View

Ryo A, Liou Y, Wulf G, Nakamura M, Lee S, Lu K . PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells. Mol Cell Biol. 2002; 22(15):5281-95. PMC: 133940. DOI: 10.1128/MCB.22.15.5281-5295.2002. View

Lu K, Zhou X . The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007; 8(11):904-16. DOI: 10.1038/nrm2261. View

Lu K . Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. Cancer Cell. 2003; 4(3):175-80. DOI: 10.1016/s1535-6108(03)00218-6. View

Li H, Wang S, Zhu T, Zhou J, Xu Q, Lu Y . Pin1 contributes to cervical tumorigenesis by regulating cyclin D1 expression. Oncol Rep. 2006; 16(3):491-6. View

Lam P, Burga L, Wu B, Hofstatter E, Lu K, Wulf G . Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer. 2008; 7:91. PMC: 2632646. DOI: 10.1186/1476-4598-7-91. View

Fukuchi M, Fukai Y, Kimura H, Sohda M, Miyazaki T, Nakajima M . Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol. 2006; 29(2):329-34. View

10.

Lu J, Hu Z, Wei S, Wang L, Liu Z, El-Naggar A . A novel functional variant (-842G>C) in the PIN1 promoter contributes to decreased risk of squamous cell carcinoma of the head and neck by diminishing the promoter activity. Carcinogenesis. 2009; 30(10):1717-21. PMC: 2757547. DOI: 10.1093/carcin/bgp171. View

11.

Yeh E, Means A . PIN1, the cell cycle and cancer. Nat Rev Cancer. 2007; 7(5):381-8. DOI: 10.1038/nrc2107. View

12.

Yeh E, Lew B, Means A . The loss of PIN1 deregulates cyclin E and sensitizes mouse embryo fibroblasts to genomic instability. J Biol Chem. 2005; 281(1):241-51. DOI: 10.1074/jbc.M505770200. View

13.

Ryo A, Nakamura M, Wulf G, Liou Y, Lu K . Pin1 regulates turnover and subcellular localization of beta-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001; 3(9):793-801. DOI: 10.1038/ncb0901-793. View

14.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

15.

Lau J, Ioannidis J, Schmid C . Quantitative synthesis in systematic reviews. Ann Intern Med. 1998; 127(9):820-6. DOI: 10.7326/0003-4819-127-9-199711010-00008. View

16.

Nakashima M, Meirmanov S, Naruke Y, Kondo H, Saenko V, Rogounovitch T . Cyclin D1 overexpression in thyroid tumours from a radio-contaminated area and its correlation with Pin1 and aberrant beta-catenin expression. J Pathol. 2004; 202(4):446-55. DOI: 10.1002/path.1534. View

17.

Han C, Lu J, Wei Q, Bondy M, Brewster A, Yu T . The functional promoter polymorphism (-842G>C) in the PIN1 gene is associated with decreased risk of breast cancer in non-Hispanic white women 55 years and younger. Breast Cancer Res Treat. 2009; 122(1):243-9. PMC: 2883663. DOI: 10.1007/s10549-009-0682-9. View

18.

Miyashita H, Mori S, Motegi K, Fukumoto M, Uchida T . Pin1 is overexpressed in oral squamous cell carcinoma and its levels correlate with cyclin D1 overexpression. Oncol Rep. 2003; 10(2):455-61. View

19.

Lu K, Liou Y, Zhou X . Pinning down proline-directed phosphorylation signaling. Trends Cell Biol. 2002; 12(4):164-72. DOI: 10.1016/s0962-8924(02)02253-5. View

20.

Chen S, Wulf G, Zhou X, Rubin M, Lu K, Balk S . Activation of beta-catenin signaling in prostate cancer by peptidyl-prolyl isomerase Pin1-mediated abrogation of the androgen receptor-beta-catenin interaction. Mol Cell Biol. 2006; 26(3):929-39. PMC: 1347015. DOI: 10.1128/MCB.26.3.929-939.2006. View